Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma

NCT01460979 is registered in ClinicalTrials.gov with AGO Study Group as lead sponsor.

NCT NCT01460979
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01460979 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma
Lead sponsor
AGO Study Group
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
November 30, 2015
Enrollment
47 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial neoplasms, genital diseases, female, ovarian diseases, ovarian neoplasms